PHILADELPHIA -- Peanut allergy immunotherapy delivered by an investigational skin patch increased the proportion of children ages 4 to 7 years who could tolerate a dose of peanut protein in the phase ...

DBV Technologies S.A. (NASDAQ: DBVT) on Tuesday released data from the VITESSE Phase 3 study assessing the safety and efficacy of VIASKIN Peanut patch for peanut-allergic children aged 4 to 7 years.

A Phase 3 trial is showing some promise that children as young as age 1 can be treated for peanut allergies. DBV Technologies released new findings in the New England Journal of Medicine this week of ...

WASHINGTON — An experimental skin patch is showing promise to treat toddlers who are highly allergic to peanuts — training their bodies to handle an accidental bite. Peanut allergy is one of the most ...

Please provide your email address to receive an email when new articles are posted on . At month 12, 46.6% of children using the Viaskin Peanut patch were treatment responders vs. 14.8% of children ...

Bottom Line: A skin patch that delivered a high dose of peanut protein reduced peanut sensitivity in children and adults with peanut allergy, findings that warrant a phase 3 trial. Why The Research Is ...

Treatment with an experimental peanut protein patch can help young children safely build tolerance to peanuts, a new study says. More than 70% of children treated with the Viaskin Peanut Patch could ...

At month 36 of VP250, 71.2% of initial placebo participants reached an eliciting dose ≥1000mg (equivalent of 3 to 4 peanut kernels) compared with 62.7% at month 12. (HealthDay News) — A peanut patch ...

Six-year-old Elias Kroboth eats about 1.5 grams of peanuts as part of his daily Oral Immunotherapy treatment plan on Thursday, July 12, 2018 in Raleigh, N.C. After gradually increasing his consumption ...

(RTTNews) - DBV Technologies (DBVT) announced that its investigational VIASKIN peanut patch met the primary endpoint in the pivotal Phase 3 VITESSE trial, demonstrating significant desensitization in ...